Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat plus paclitaxel/carboplatin versus placebo plus paclitaxel/carboplatin in advanced NSCLC
2006-005122-23Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Vorinostat + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoints: overall survival, safety and tolerability and 1 more. Started Jan 2007; status: completed.
02
Drugs
vorinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-005122-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005122-23.